Selected research
Market Structure
Global Acute Kidney Injury Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Acute Kidney Injury Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Acute Kidney Injury Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Acute Kidney Injury Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Acute Kidney Injury Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Acute Kidney Injury Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Acute Kidney Injury Drugs include Fresenius Medical Care AG & Co. KGaA, B. Braun Melsungen AG, Quark Pharmaceuticals, Baxter International, LG Chem, Asahi Kasei Medical and Angion Biomedica Corp, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Acute Kidney Injury Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Acute Kidney Injury Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Acute Kidney Injury Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Acute Kidney Injury Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Acute Kidney Injury Drugs Segment by Company
Fresenius Medical Care AG & Co. KGaA
B. Braun Melsungen AG
Quark Pharmaceuticals
Baxter International
LG Chem
Asahi Kasei Medical
Angion Biomedica Corp
Acute Kidney Injury Drugs Segment by Type
Intrinsic Acute Kidney Injury
Postrenal Acute Kidney Injury
Prerenal Acute Kidney Injury
Others
Acute Kidney Injury Drugs Segment by Application
Hospital
Clinic
Acute Kidney Injury Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Kidney Injury Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Acute Kidney Injury Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Kidney Injury Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Acute Kidney Injury Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acute Kidney Injury Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Acute Kidney Injury Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Acute Kidney Injury Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Intrinsic Acute Kidney Injury
- Postrenal Acute Kidney Injury
- Prerenal Acute Kidney Injury
- Others
Applications
- Hospital
- Clinic
Companies covered
- Fresenius Medical Care AG & Co. KGaA
- B. Braun Melsungen AG
- Quark Pharmaceuticals
- Baxter International
- LG Chem
- Asahi Kasei Medical
- Angion Biomedica Corp
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Acute Kidney Injury Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Acute Kidney Injury Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Acute Kidney Injury Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Acute Kidney Injury Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Acute Kidney Injury Drugs Market Dynamics
- 2.1 Acute Kidney Injury Drugs Industry Trends
- 2.2 Acute Kidney Injury Drugs Industry Drivers
- 2.3 Acute Kidney Injury Drugs Industry Opportunities and Challenges
- 2.4 Acute Kidney Injury Drugs Industry Restraints
3 Acute Kidney Injury Drugs Market by Manufacturers
- 3.1 Global Acute Kidney Injury Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Acute Kidney Injury Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Acute Kidney Injury Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Acute Kidney Injury Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Acute Kidney Injury Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Acute Kidney Injury Drugs Manufacturers, Product Type & Application
- 3.7 Global Acute Kidney Injury Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Acute Kidney Injury Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Acute Kidney Injury Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Acute Kidney Injury Drugs Tier 1, Tier 2, and Tier 3
4 Acute Kidney Injury Drugs Market by Type
- 4.1 Acute Kidney Injury Drugs Type Introduction
- 4.1.1 Intrinsic Acute Kidney Injury
- 4.1.2 Postrenal Acute Kidney Injury
- 4.1.3 Prerenal Acute Kidney Injury
- 4.1.4 Others
- 4.2 Global Acute Kidney Injury Drugs Sales by Type
- 4.2.1 Global Acute Kidney Injury Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Acute Kidney Injury Drugs Sales by Type (2021-2032)
- 4.2.3 Global Acute Kidney Injury Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Acute Kidney Injury Drugs Revenue by Type
- 4.3.1 Global Acute Kidney Injury Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Acute Kidney Injury Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Acute Kidney Injury Drugs Revenue Market Share by Type (2021-2032)
5 Acute Kidney Injury Drugs Market by Application
- 5.1 Acute Kidney Injury Drugs Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.2 Global Acute Kidney Injury Drugs Sales by Application
- 5.2.1 Global Acute Kidney Injury Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Acute Kidney Injury Drugs Sales by Application (2021-2032)
- 5.2.3 Global Acute Kidney Injury Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Acute Kidney Injury Drugs Revenue by Application
- 5.3.1 Global Acute Kidney Injury Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Acute Kidney Injury Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Acute Kidney Injury Drugs Revenue Market Share by Application (2021-2032)
6 Global Acute Kidney Injury Drugs Sales by Region
- 6.1 Global Acute Kidney Injury Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Acute Kidney Injury Drugs Sales by Region (2021-2032)
- 6.2.1 Global Acute Kidney Injury Drugs Sales by Region (2021-2026)
- 6.2.2 Global Acute Kidney Injury Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Acute Kidney Injury Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Acute Kidney Injury Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Acute Kidney Injury Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Acute Kidney Injury Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Acute Kidney Injury Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Acute Kidney Injury Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Acute Kidney Injury Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Acute Kidney Injury Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Acute Kidney Injury Drugs Revenue by Region
- 7.1 Global Acute Kidney Injury Drugs Revenue by Region
- 7.1.1 Global Acute Kidney Injury Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Acute Kidney Injury Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Acute Kidney Injury Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Acute Kidney Injury Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Acute Kidney Injury Drugs Revenue (2021-2032)
- 7.2.2 North America Acute Kidney Injury Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Acute Kidney Injury Drugs Revenue (2021-2032)
- 7.3.2 Europe Acute Kidney Injury Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Acute Kidney Injury Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Acute Kidney Injury Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Acute Kidney Injury Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Acute Kidney Injury Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Fresenius Medical Care AG & Co. KGaA
- 8.1.1 Fresenius Medical Care AG & Co. KGaA Company Information
- 8.1.2 Fresenius Medical Care AG & Co. KGaA Business Overview
- 8.1.3 Fresenius Medical Care AG & Co. KGaA Acute Kidney Injury Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Fresenius Medical Care AG & Co. KGaA Acute Kidney Injury Drugs Product Portfolio
- 8.1.5 Fresenius Medical Care AG & Co. KGaA Recent Developments
- 8.2 B. Braun Melsungen AG
- 8.2.1 B. Braun Melsungen AG Company Information
- 8.2.2 B. Braun Melsungen AG Business Overview
- 8.2.3 B. Braun Melsungen AG Acute Kidney Injury Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 B. Braun Melsungen AG Acute Kidney Injury Drugs Product Portfolio
- 8.2.5 B. Braun Melsungen AG Recent Developments
- 8.3 Quark Pharmaceuticals
- 8.3.1 Quark Pharmaceuticals Company Information
- 8.3.2 Quark Pharmaceuticals Business Overview
- 8.3.3 Quark Pharmaceuticals Acute Kidney Injury Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Quark Pharmaceuticals Acute Kidney Injury Drugs Product Portfolio
- 8.3.5 Quark Pharmaceuticals Recent Developments
- 8.4 Baxter International
- 8.4.1 Baxter International Company Information
- 8.4.2 Baxter International Business Overview
- 8.4.3 Baxter International Acute Kidney Injury Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Baxter International Acute Kidney Injury Drugs Product Portfolio
- 8.4.5 Baxter International Recent Developments
- 8.5 LG Chem
- 8.5.1 LG Chem Company Information
- 8.5.2 LG Chem Business Overview
- 8.5.3 LG Chem Acute Kidney Injury Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 LG Chem Acute Kidney Injury Drugs Product Portfolio
- 8.5.5 LG Chem Recent Developments
- 8.6 Asahi Kasei Medical
- 8.6.1 Asahi Kasei Medical Company Information
- 8.6.2 Asahi Kasei Medical Business Overview
- 8.6.3 Asahi Kasei Medical Acute Kidney Injury Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Asahi Kasei Medical Acute Kidney Injury Drugs Product Portfolio
- 8.6.5 Asahi Kasei Medical Recent Developments
- 8.7 Angion Biomedica Corp
- 8.7.1 Angion Biomedica Corp Company Information
- 8.7.2 Angion Biomedica Corp Business Overview
- 8.7.3 Angion Biomedica Corp Acute Kidney Injury Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Angion Biomedica Corp Acute Kidney Injury Drugs Product Portfolio
- 8.7.5 Angion Biomedica Corp Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Acute Kidney Injury Drugs Value Chain Analysis
- 9.1.1 Acute Kidney Injury Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Acute Kidney Injury Drugs Production Mode & Process
- 9.2 Acute Kidney Injury Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Acute Kidney Injury Drugs Distributors
- 9.2.3 Acute Kidney Injury Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst